3 results match your criteria: "United States. Electronic address: kkowdley@liverinstitutenw.org.[Affiliation]"
Impact of COVID-19 pandemic on alcohol-related hepatitis admissions: Analysis of nationwide data 2016-2020.
Am J Med Sci
September 2023
Liver Institute Northwest, Seattle, WA, United States; Elson Floyd College of Medicine, Washington State University, Spokane, WA, United States. Electronic address:
Article Synopsis
- The study examines the impact of the COVID-19 pandemic on alcohol-related hepatitis (ARH) cases in the U.S., finding a significant rise in hospitalizations from 2019 to 2020.
- Data from the National Inpatient Sample showed that ARH cases increased by 12.4% in 2020, with women experiencing a 14.2% rise and men a 12.2% rise compared to previous years.
- Additionally, mortality rates for ARH patients also escalated sharply, with deaths increasing by 24.6% in 2020, indicating more severe cases during the pandemic.
A randomized, placebo-controlled, phase II study of obeticholic acid for primary sclerosing cholangitis.
J Hepatol
July 2020
Division of Gastroenterology and Hepatology, University of California, Davis, Sacramento, CA, USA.
Background & Aims: Primary sclerosing cholangitis (PSC) is a rare, cholestatic liver disease with no currently approved therapies. Obeticholic acid (OCA) is a potent farnesoid X receptor (FXR) agonist approved for the treatment of primary biliary cholangitis. We investigated the efficacy and safety of OCA in patients with PSC.
View Article and Find Full Text PDFCurrent and potential treatments for primary biliary cholangitis.
Lancet Gastroenterol Hepatol
March 2020
Liver Institute Northwest, Seattle, WA, USA. Electronic address:
Up to 40% of patients with primary biliary cholangitis have an incomplete response to first-line treatment with ursodeoxycholic acid. Obeticholic acid was approved by the US Food and Drug Administration in 2016 as a second-line treatment for patients with primary biliary cholangitis who are unresponsive to ursodeoxycholic acid; however, approximately 50% of patients might need additional treatments to reach therapeutic goals. A considerable need exists for effective treatment options to prevent progression to liver transplantation or death in these patients.
View Article and Find Full Text PDF